FURMO-006 // A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced

You are being asked to participate in this study because you have a type of lung cancer called non-small-cell lung cancer (NSCLC) that has spread and because it contains certain mutations (changes) in a gene called epidermal growth factor receptor (EGFR). The EGFR mutations lead to cancers in the lung such as NSCLC. This study is for people with uncommon EGFR mutation subtypes where the data for the best treatment is less known due to their rarity. A drug called firmonertinib is being developed for the treatment of NSCLC with mutations in EGFR with a specific change in the P-loop and alpha C-helix compressing (PACC) region. These changes in EGFR PACC can cause lung cancer to grow more rapidly. The purpose of the study is to learn about the effectiveness and safety of firmonertinib and to compare the effects, good or bad, with those of osimertinib or afatinib.

Are you Eligible? (Inclusion Criteria)

• Be 18 years of age or older - Not pregnant/breastfeeding or intending to become pregnant/breastfeed throughout the study - Have diagnosed non small cell lung cancer (NSCLC) - Must be able to swallow pills